List of bibliographic references indexed by agonists
Number of relevant bibliographic references: 26.
[0-20] [
0 - 20][
0 - 26][
20-25][
20-40]
Ident. | Authors (with country if any) | Title |
---|
000990 (2014) |
Kristian Thorlund [Canada, États-Unis] ; Ping Wu [Canada] ; Eric Druyts [Canada] ; Shawn Eapen [Canada] ; Edward J. Mills [États-Unis, Canada] | Nonergot dopamine-receptor agonists for treating Parkinson’s disease – a network meta-analysis |
000B86 (2014) |
Santiago Perez-Lloret [France] ; María Ver Nica Rey [France] ; James Crispo [Canada] ; Daniel Krewski [Canada] ; Marise Lapeyre-Mestre [France] ; Jean-Louis Montastruc [France] ; Olivier Rascol [France] | Risk of heart failure following treatment with dopamine agonists in Parkinson's disease patients |
000C03 (2014) |
Francesca Antonelli [Canada] ; JI HYUN KO [Canada] ; Janis Miyasaki [Canada] ; Anthony E. Lang [Canada] ; Sylvain Houle [Canada] ; Franco Valzania [Italie] ; Nicola J. Ray [Canada] ; Antonio P. Strafella [Canada] | Dopamine-Agonists and Impulsivity in Parkinson's Disease: Impulsive Choices vs. Impulsive Actions |
000D99 (2013) |
Francesca Antonelli [Canada] ; Ji Hyun Ko [Canada] ; Janis Miyasaki [Canada] ; Anthony E. Lang [Canada] ; Sylvain Houle [Canada] ; Franco Valzania [Italie] ; Nicola J. Ray [Canada] ; Antonio P. Strafella [Canada] | Dopamine-Agonists and Impulsivity in Parkinson’s Disease: Impulsive Choices vs. Impulsive Actions |
001956 (2011) |
Ngoc-Duc Doan [Canada] ; Steve Bourgault [Canada] ; Agnieszka Dejda [Canada] ; Myriam Letourneau [Canada] ; Michel Detheux [Belgique] ; David Vaudry [Canada, France] ; Hubert Vaudry [Canada, France] ; David Chatenet [Canada] ; Alain Fournier [Canada] | Design and in vitro characterization of PAC1/VPAC1-selective agonists with potent neuroprotective effects |
001E57 (2009) |
Thilo Van Eimeren [Canada] ; Bénédicte Ballanger [Canada] ; Giovanna Pellecchia [Canada] ; Janis M. Miyasaki [Canada] ; Anthony E. Lang [Canada] ; Antonio P. Strafella [Canada] | Dopamine Agonists Diminish Value Sensitivity of the Orbitofrontal Cortex: A Trigger for Pathological Gambling in Parkinson’s Disease? |
002002 (2009) |
Philip Seeman [Canada] ; Hong-Chang Guan [Canada] | Glutamate agonists for treating schizophrenia have affinity for dopamine D2High and D3 receptors |
002685 (2007) |
Bryan L. Roth [États-Unis] ; René Schade [Allemagne] ; Frank Andersohn [Allemagne] ; Samy Suissa [Canada] ; Wilhelm Haverkamp [Allemagne] ; Edeltraut Garbe [Allemagne] | Dopamine agonists and the risk of cardiac-valve regurgitation |
002925 (2006) |
Jordi Gomez-Ramirez [Canada] ; Tom H. Johnston [Canada] ; Naomi P. Visanji [Canada] ; Susan H. Fox [Canada] ; Jonathan M. Brotchie [Canada] | Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of parkinson's disease |
002D04 (2004) |
Judit Horvath [Suisse] ; Robin D. Fross [États-Unis] ; Galit Kleiner-Fisman [Canada] ; René Lerch [Suisse] ; Hans Stalder [Suisse] ; Suzanne Liaudat [Suisse] ; William J. Raskoff [États-Unis] ; Keith D. Flachsbart [États-Unis] ; Harry Rakowski [Canada] ; Jean-Claude Pache [Suisse] ; Pierre R. Burkhard [Suisse] ; Anthony E. Lang [Canada] | Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonists |
002D10 (2004) |
Ajmal Razmy [Canada] ; Anthony E. Lang [Canada] ; Colin M. Shapiro [Canada] | Predictors of impaired daytime sleep and wakefulness in patients with Parkinson disease treated with older (ergot) vs newer (nonergot) dopamine agonists |
003310 (2001) |
Mahyar Etminan [Canada] ; Ali Samii [États-Unis] ; Bahi Takkouche [Espagne] ; Paula A. Rochon [Canada] | Increased risk of somnolence with the new dopamine agonists in Patients with Parkinson's disease: A meta-analysis of randomised controlled trials |
003336 (2001) |
Olivier Rascol [France] ; Joaquim J. Ferreira [Portugal] ; Claire Thalamas [France] ; Monique Galitsky [France] ; Jean-Louis Montastruc [France] | Dopamine agonists: Their role in the management of Parkinson's disease |
003595 (2000) |
T. J. Hudzik [États-Unis] ; A. Howell [États-Unis] ; K. Payza [Canada] ; A. J. Cross [États-Unis] | Antiparkinson potential of δ-opioid receptor agonists |
003622 (1999) |
D B Calne [Canada] | Differentiation of dopamine agonists and their role in the treatment of Parkinson's disease. |
003801 (1999) |
D. E. Hobson [Canada] ; E. Pourcher [Canada] ; W. R. W. Martin [Canada] | Ropinirole and pramipexole, the new agonists |
003802 (1999) |
P. J. Blanchet [Canada] | Rationale for use of dopamine agonists in Parkinson's disease : Review of ergot derivatives |
004454 (1993) |
P. Blanchet [Canada] ; P. J. Bedard [Canada] ; D. R. Britton ; J. W. Kebabian | Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-exposed monkeys |
004622 (1992) |
D. B. King [Canada] | The place of the dopaminergic agonists in the treatment of Parkinson's disease the view from thye trenches |
004629 (1992) |
H. A. Robertson [Canada] | Synergistic interactions of D1- and D2-selective dopamine agonists in animal models for Parkinson's disease : sites of action and implications for the pathogenesis of dyskinesias |
004663 (1992) |
C. W. Olanow [États-Unis] | A rationale for dopamine agonists as primary therapy for Parkinson's disease |
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i -k "agonists"
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Title.i \
-Sk "agonists" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= indexItem
|index= Title.i
|clé= agonists
}}
| This area was generated with Dilib version V0.6.29. Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022 | |